Pierre Sayad compensation by year
FENNEC PHARMACEUTICALS Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $464,081 |
| Bonus | $0 |
| Stock awards | $311,000 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $775,081 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: FENNEC PHARMACEUTICALS INC. DEF 14A filed April 28, 2026, accession 0001104659-26-050339, and prior-year filings. Open the filing on EDGAR.
FENNEC PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Robert Andrade | Chief Financial Officer | $1,873,024 |
| Jeffrey Hackman | Chief Executive Officer | $1,722,154 |
| Pierre Sayad · this page | Chief Medical Officer | $775,081 |
The full FENNEC PHARMACEUTICALS compensation record
free company briefThis page is one person within FENNEC PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order FENNEC PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are FENNEC PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat